A3SMO® based first-in-class medicines and diagnostics for autoimmune & genetic diseases

A3SMO® form stable, tunable, predictable molecular surfaces with short chain-lengths. These properties combine the benefits and eliminate the drawbacks of small molecules and large antibodies.

Contact Us

Our Mission

Discover, develop and commercialise Artificial Amino Acid based medicines and diagnostics to treat patients with autoimmune and genetic diseases with the greatest unmet medical needs where current therapies are inadequate.

Contact Us

Our approach

The A3SMO®​ Platform - the breakthrough molecular solution for the custom design of self-assembling artificial amino acid-based small molecules. It increases the drug-likeness of the molecules and creates first-in-class medicines to treat patients with major unmet clinical needs.

Who we are

Gábor Heltovics
President
LinkedIn
István Mándity
Chief Chemistry Officer
LinkedIn
József Maléth
Chief Scientific Officer
LinkedIn
Beáta Mándityné Huszka
Head of Peptide Chemistry Laboratory
LinkedIn
Petra Pallagi
Head of Pre-clinical Research
LinkedIn

Who we are

Ladon Therapeutics is a clinical stage biopharmaceutical company

Featured news

10 November 2022
Technology
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

August 11, 2023
Technology
The A3SMO® Platform, solid-phase HT synthesizer system is online!

The development of artificial amino acid-based pharmaceutics is a hot topic in the pharmaceutical industry and in basic research.

October 25, 2021
Technology
Megkezdődött a„Proteomimetikus peptid gyógyszerek fejlesztése és gyártása nagyáteresztő képességű innovatív platformon” című pályázat2020-1.1.5-GYORSÍTÓSÁV-2021-00009

AzEpi-Pharma Gyógyszerkutató Korlátolt Felelősségű Társasága „Proteomimetikus peptid gyógyszerek fejlesztése és gyártása nagyáteresztő képességű innovatív platformon” címmel 114,34millió forint vissza nem térítendő támogatást nyert a Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal által meghirdetett „2020-1.1.5-GÍORSÍTÓSÁV” kódszámú, „GYORSÍTÓSÁV” felhívásán.

July 20, 2020
Technology
CalciMedica and EpiPharma Enter into Research Collaboration to Discoverand Develop CRAC Channel Inhibitor Therapies

CalciMedica and EpiPharma today announced that they have entered into a collaboration agreement to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform

Ready to make the first step towards your new future?

We’re here to help.

Contact Us